Ингибиторы CDK4/6 в терапии метастатического рака молочной железы. Выбор оптимальной терапии эстроген-рецептор-положительного HER2-отрицательного метастатического рака молочной железы: общероссийский анализ предпочтений врачей («Прометей») – первые результаты опроса
https://doi.org/10.17650/1994-4098-2020-16-3-37-45
Аннотация
Ключевые слова
Об авторах
Е. В. АртамоноваРоссия
Елена Владимировна Артамонова
115478 Москва, Каширское шоссе, 24
117997 Москва, ул. Островитянова, 1
129110 Москва, ул. Щепкина, 61/2, корп. 1
Е. И. Коваленко
Россия
115478 Москва, Каширское шоссе, 24
Л. В. Болотина
Россия
125284 Москва, 2-й Боткинский проезд, 3
М. Б. Стенина
Россия
115478 Москва, Каширское шоссе, 24
Р. В. Орлова
Россия
199034 Санкт-Петербург, Университетская набережная, 7–9
198255 Санкт-Петербург, проспект Ветеранов, 56
М. А. Мухина
Россия
123112 Москва, Пресненская набережная, 10
Список литературы
1. Cardoso F., Spence D., Mertz S. et al. Global analysis of advanced/metastatic breast cancer: decade report (20052015). Breast 2018;39:131–8. DOI: 10.1016/j.breast.2018.03.002.
2. Cardoso F., Sencus E., Costa A. et al. 4 th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC4). Ann Oncol 2018;(29):1634–57.
3. Rugo H.S., Rumble R.B., Macrae E. et al. Endocrine therapy for hormone receptorpositive metastatic breast cancer: American Society of Clinical Oncology guideline. JCO 2016. DOI: 10.1200/JCO.2016.67.1487.
4. Wilcken N., Hornbuckle J., Ghersi D. Chemotherapy alone versus endocrine therapy alone for metastatic breast cancer. Cochrane Database Syst Rev 2003;(2):CD002747. DOI: 10.1002/14651858.CD002747.
5. Cardoso F., Costa A., Norton L. et al. ESO-ESMO 2 nd international consensus guidelines for advanced breast cancer (ABC2). Ann Oncol 2014;25(10):1871–88.
6. Hirama T., Koeffler Н.Р. Role of the Cyclin-dependent kinase inhibitors in the development of cancer. Blood 1995;86:841–54.
7. Fry D., Harvey P.J., Keller P.R. et al. Specific Inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts. Mol Cancer Ther 2004;3:1427–37.
8. Choi Y.J., Anders L. Signaling through cyclin D-dependent kinases. Oncogene 2014;33:1890–903. DOI: 10.1038/onc.2013.137.
9. The Nobel Prize in Physiology or Medicine 2001. Available at: http://www.nobelprize.org/nobel_prizes/medicine/laureates/2001/.
10. Finn R.S., Dering J., Conklin D. et al. PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptorpositive human breast cancer cell lines in vitro. Breast Cancer Res 2009;11(5):R77. DOI: 10.1186/bcr2419.
11. Lamb R., Lehn S., Rogerson L. et al. Cell cycle regulators cyclin D1 and CDK4/6 have estrogen receptordependent divergent functions in breast cancer migration and stem cell-like activity. Cell Cycle 2013;12(15):2384–94. DOI: 10.4161/cc.25403.
12. Im S.A., Lu Y.S., Bardia A. et al. Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer. N Engl J Med 2019;381(4):307–16. DOI: 10.1056/NEJMoa1903765.
13. Slamon D.J., Neven P., Chia S. et al. Overall survival with ribociclib plus fulvestrant in advanced breast cancer. N Engl J Med 2020;382(6):514–24. DOI: 10.1056/NEJMoa1911149.
14. Slamon D.J., Neven P., Chia S. et al. Phase III randomized study of ribociclib and fulvestrant in hormone receptorpositive, human epidermal growth factor receptor 2-negative advanced breast cancer: MONALEESA-3. J Clin Oncol 2018;36(24):2465–72. DOI: 10.1200/JCO.2018.78.9909.
15. Sledge G.W.Jr., Toi M., Neven P. et al. The effect of abemaciclib plus fulvestrant on overall survival in hormone receptorpositive, ERBB2-negative breast cancer that progressed on endocrine therapy MONARCH 2: A Randomized Clinical Trial. JAMA Oncol 2019;6(1):116–24. DOI: 10.1001/jamaoncol.2019.4782.
16. Sledge G.W.Jr., Toi M., Neven P. et al. MONARCH 2: Abemaciclib in combination with fulvestrant in women with HR+/HER2– advanced breast cancer who had progressed while receiving endocrine therapy. J Clin Oncol 2017;35(25):2875–84. DOI: 10.1200/JCO.2017.73.7585.
17. Tripathy D., Im S.A., Colleoni M. et al. Ribociclib plus endocrine therapy for premenopausal women with hormonereceptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial. Lancet Oncol 2018;19(7):904–15. DOI: 10.1016/S1470-2045(18)30292-4.
18. Finn R.S., Martin M., Rugo H.S. et al. Palbociclib and letrozole in advanced breast cancer. N Engl J Med 2016;375(20):1925–36. DOI: 10.1056/NEJMoa1607303.
19. Rugo H.S., Finn R.S., Dieras V. et al. Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive/ human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-up. Breast Cancer Res Treat 2019;174(3):719–29. DOI: 10.1007/s10549-018-05125-4.
20. Johnston S., Martin M., Di Leo A. et al. MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer. NPJ Breast Cancer 2019;5:5. DOI: 10.1038/s41523018-0097-z.
21. Cristofanilli M., Turner N.C., Bondarenko I. et al. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptorpositive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial. Lancet Oncol 2016;17(4):425–39. DOI: 10.1016/S1470-2045(15)00613-0.
22. Cardoso F., Paluch-Shimon S., Senkus E. et al. 5 th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Ann Oncol 2020. DOI: 10.1016/j.annonc.2020.09.010.
23. Giuliano M., Schettini F., Rognoni C. et al. Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2negative, metastatic breast cancer: a systematic review and network metaanalysis. Lancet Oncol 2019;20(10):1360–9. DOI: 10.1016/S1470-2045(19)30420-6.
24. DeMichele A., Cristofanili M., Brufsky A. Overall survival for first-line palbociclib plus letrozole vs letrozole alone for HR+/ HER2– metastatic breast cancer patients in US real-world clinical practice. SABCS 2019. Poster P1-19-02.
25. Waller J., Mitra D., Mycock K. et al. Treatment patterns and clinical outcomes in patients receiving palbociclib for hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced or metastatic breast cancer in Argentina: The IRIS Study. J Glob Oncol 2019;5:JGO1800239. DOI: 10.1200/JGO.18.00239.
26. Taylor-Stokes G., Mitra D., Waller J. et al. Treatment patterns and clinical outcomes among patients receiving palbociclib in combination with an aromatase inhibitor or fulvestrant for HR+/HER2-negative advanced/metastatic breast cancer in real-world settings in the US: Results from the IRIS study. Breast 2019;43:22–7. DOI: 10.1016/j.breast.2018.10.009.
27. Rocque G., Blum J.L., Montero A. et al. Quality of life in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer treated with palbociclib in realworld practice settings. San Antonio Breast Cancer Symposium, December 10–14, 2019. Abstract PD10-03.
28. De Laurentiis M., Harbeck N., Lawet E. et al. Real-world treatment patterns and clinical outcomes among women with HR+/HER2– advanced or metastatic breast cancer treated in real-world settings in Italy and Germany. San Antonio Breast Cancer Symposium, December 10–14, 2019. Poster P3-11-25.
29. Welt A., Thill M., Stickeler E. et al. What affects the choice of first-line treatment for hormone-receptorpositive, HER2-negative advanced breast cancer? Data from the German research platform OPAL. Poster 342Р. Presented at: ESMO 2020. Ann Oncol 2020;S373–S374. DOI: 10.1016/j.annonc.2020.08.426.
30. Howie L.J., Singh H., Bloomquist E. et al. Outcomes of older women with hormone receptor-positive, human epidermal growth factor receptor-negative metastatic breast cancer treated with a CDK4/6 inhibitor and an aromatase inhibitor: An FDA pooled analysis. J Clin Oncol 2019;36:3475–483. DOI: 10.1200/JCO.18.02217.
31. Robertson J.F.R., Bondarenko I.M., Trishkina E. et al. Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial. Lancet 2017;388:2997–3005.
32. Llombart-Cussac A., Pérez-García J.M., Bellet M. et al. PARSIFAL: A randomized, multicenter, open-label, phase II trial to evaluate palbociclib in combination with fulvestrant or letrozole in endocrine-sensitive patients with estrogen receptor (ER)+/HER2metastatic breast cancer. J Clin Oncol 2020;38(15 Suppl):1007.
Рецензия
Для цитирования:
Артамонова Е.В., Коваленко Е.И., Болотина Л.В., Стенина М.Б., Орлова Р.В., Мухина М.А. Ингибиторы CDK4/6 в терапии метастатического рака молочной железы. Выбор оптимальной терапии эстроген-рецептор-положительного HER2-отрицательного метастатического рака молочной железы: общероссийский анализ предпочтений врачей («Прометей») – первые результаты опроса. Опухоли женской репродуктивной системы. 2020;16(3):37-45. https://doi.org/10.17650/1994-4098-2020-16-3-37-45
For citation:
Artamonova E.V., Kovalenko E.I., Bolotina L.V., Stenina M.B., Orlova R.V., Mukhina M.A. CDK4/6 inhibitors in the treatment of metastatic breast cancer. Choosing optimal therapy for estrogen-receptor-positive HER2-negative metastatic breast cancer: analysis of doctors’ preferences (“Prometheus”) in Russia – first results of the survey. Tumors of female reproductive system. 2020;16(3):37-45. (In Russ.) https://doi.org/10.17650/1994-4098-2020-16-3-37-45